IMG_5768.JPG

marta rychert, BA, LLM, PhD

Marta is a Research Officer at the SHORE & Whariki Research Centre. Her work lies at the intersection of health, policy and law, with particular focus on the legal aspects of regulating AOD (alcohol and other drugs). This includes policy responses to new psychoactive substances (NPS, “legal highs”), new regulatory approaches to recreational cannabis, medicinal cannabis law reform and regulation of other psychoactive products such as alcohol, tobacco and e-cigarettes.

Her PhD critically analysed New Zealand’s Psychoactive Substances Act 2013 and its implementation process. She currently leads a Marsden project investigating not-for-profit approaches to cannabis law reform. Prior to joining SHORE, she interned at the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) in Lisbon, where she analysed the drug policies of European Union countries. As well as a PhD in Public Health (Massey University, New Zealand), she holds a Master’s Degree in Law (University of Warsaw, Poland).

Email: m.rychert@massey.ac.nz


publications

Rychert, M., & Wilkins, C. (2019). A 'community enterprise' model for recreational cannabis: Lessons from Alcohol Licensing Trusts in New Zealand. International Journal of Drug Policy. In press.

Rychert, M., & Wilkins, C. (2019). New Zealand's review of the Psychoactive Substances Act 2013: a missed learning opportunity ahead of the national cannabis law reform referendum? Addiction. In press.

Rychert, M., & Wilkins, C. (2018). Understanding the development of a regulated market approach to new psychoactive substances (NPS) in New Zealand using Punctuated Equilibrium Theory. Addiction, 113(11), 2132-2139. A457

Wilkins, C., Rychert, M., Romeo, J., & Randerson, S. (2019). Smoke in our eyes: the Sense Partners’ evaluation of the legalisation of cannabis in New Zealand [Editorial]. New Zealand Medical Journal, 132(1490), 6-9. https://www.nzma.org.nz/journal/read-the-journal/all-issues/2010-2019/2019/vol-2132-no-1490-2022-february-2019/7811. A456

Wilkins, C., Romeo, J., Rychert, M., Prasad, J., & Graydon-Guy, T. (2018). Determinants of high availability of methamphetamine, cannabis, LSD and ecstasy in New Zealand: Are drug dealers promoting methamphetamine rather than cannabis? International Journal of Drug Policy, 61, 15-22. doi: 10.1016/j.drugpo.2018.09.007. A455

Wilkins, C., & Rychert, M. (2018). Responding to a new wave of high potency synthetic cannabinoids [Editorial]. New Zealand Medical Journal, 131(1481), 6-8. A449

Rychert, M., & Wilkins, C. (2018). A critical analysis of the implementation of a legal regulated market for new psychoactive substances ("legal highs") in New Zealand. International Journal of Drug Policy, 55, 88-94. A425

Rychert, M., Wilkins, C., Parker, K., & Witten, K. (2017). Are government-approved products containing new psychoactive substances perceived to be safer and more socially acceptable than alcohol, tobacco and illegal drugs? Findings from a survey of police arrestees in New Zealand. Drug and Alcohol Review, published online Dec 29, doi: 10.1111/dar.12655. A416

Rychert, M., Wilkins, C., & Witten, K. (2017). “Lost in translation”: Issues with the establishment of a legal market for “low risk” psychoactive products (“legal highs”) in New Zealand. Drugs: Education, Prevention and Policy, 1-8. doi: 10.1080/09687637.2017.1282422

Rychert, M. & Wilkins, C. (2017), Issues with monitoring the safety of psychoactive products under a legal regulated market for new psychoactive substances (NPS) (‘legal highs’) in New Zealand, Drug and Alcohol Review, 36(5), 589-596.

Rychert, M. & Wilkins, C. (2017), Thirty-one psychoactive plants exempted from New Zealand’s Psychoactive Substances Act 2013 [Letter] Addiction, 112(1), 181-182

Rychert, M. & Wilkins, C. (2016), Legal high industry business and lobbying strategies under a legal  market for new psychoactive substances (NPS, 'legal highs') in New Zealand, International Journal of Drug Policy, 37, 90-97.

Rychert, M. & Wilkins, C. (2016). What products are considered psychoactive under New Zealand's legal market for new psychoactive substances (NPS, ‘legal highs’)? Implications for law enforcement and penalties, Drug Testing and Analysis, 8(8), 768–778

Wilkins, C., Prasad, J., Wong, K.C., Graydon-Guy, T & Rychert, M. (2016).  An exploratory study of the health harms and utilisation of health services of frequent legal high users under the interim regulated legal high market in central Auckland, New Zealand Medical Journal, 129 (1431), 51-58.

Rychert, M. & Wilkins, C. (2015). Did we have the wrong debate about Elixinol™ and medicinal cannabis? [Letter] New Zealand Medical Journal, 128(1421), 69-70.

Rychert, M. & Wilkins, C. (2015). The challenge of a ban on animal testing for the development of a regulated legal market for new psychoactive substances (NPS) ('legal highs') in New Zealand: Issues and options for resolution. International Journal of Drug Policy, 26, 1273-1278.

Rychert, M. and Wilkins, C. (2015),  Is the recent ban on animal testing of legal high products a fatal blow to the development of a legal market for ‘low-risk’ psychoactive products in New Zealand? [Letter] Addiction 110(4), 714-715.